Lineage Cell Therapeutics
Open
$1.24
Prev. Close
$1.24
High
$1.25
Low
$1.24
Market Snapshot
$298.91M
-4.7
-0.10
$9.5M
75
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The firm programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 72 full-time employees. The firm programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Recently from Cashu
Lineage Cell Therapeutics: Leading Innovations in the Growing Cell Therapy Market
### Lineage Cell Therapeutics: Pioneering Advancements in Cell Therapy Lineage Cell Therapeutics is at the forefront of the evolving landscape of regenerative medicine, particularly through its focus…
Lineage Cell Therapeutics Advances in Regenerative Medicine and Cell Therapy Innovation
Lineage Cell Therapeutics Embraces New Frontiers in Cell Therapy Development Lineage Cell Therapeutics stands poised to make significant strides in the expansive field of regenerative medicine as the…
Lineage Cell Therapeutics: Innovating Cell Encapsulation for Diabetes Management Revolution
Cell Encapsulation Technology: A Game Changer for Diabetes Management Avant Technologies Inc. is at the forefront of innovation in the cell therapy manufacturing sector, particularly with its groundbr…
Lineage Cell Therapeutics Advances Innovative Cell Therapies for Degenerative Diseases
Lineage Cell Therapeutics Focuses on Advancing Cell Therapy Innovations Lineage Cell Therapeutics continues to push the boundaries of regenerative medicine as it advances its innovative cell therapies…